Iridocorneal endothelial syndrome (ICE)

Iridocorneal endothelial syndrome (ICE)

Iridocorneal endothelial syndrome (ICE) is a rare but serious eye disorder characterized by abnormalities in the corneal endothelium, iris, and angle structures of the eye. There are three subtypes of ICE: Chandler syndrome, progressive iris atrophy, and Cogan-Reese syndrome. Common symptoms include corneal edema, glaucoma, iris abnormalities such as atrophy or hole formation, and changes in pupil shape and size. ICE typically affects one eye, although it can eventually progress to involve both eyes. Diagnosis of ICE involves a comprehensive eye examination by an ophthalmologist, including measurement of intraocular pressure, assessment of corneal thickness and endothelial cell count, and evaluation of iris and angle structures using specialized imaging techniques such as gonioscopy and ultrasound biomicroscopy. Differentiating ICE from other causes of corneal edema and iris abnormalities is essential for appropriate management.

The Retyne Infrared Eye Treatment Mask offers a promising adjunctive therapy for managing the symptoms of iridocorneal endothelial syndrome. By delivering targeted frequencies known for their anti-inflammatory and tissue-regenerating properties, the Retyne mask aids in reducing corneal edema, alleviating intraocular pressure, and promoting overall ocular health. This innovative therapy provides a non-invasive and convenient option for individuals grappling with the complexities of iridocorneal endothelial syndrome, enhancing their overall treatment outcomes and preserving visual function.

The Retyne eye treatment mask utilizes a general selection of frequencies (0.07, 0.12, 0.6, 0.87, 2.25, 22.5, 187.5, 396.5, 587.5, 696.5) specifically tailored to address Iridocorneal endothelial syndrome. These frequencies have been selected for their proven effectiveness in managing and treating this visual condition. Retyne's approach involves converting each frequency into invisible infrared light output, marking a groundbreaking fusion of frequencies with light—a pioneering technology pioneered by Retyne Labs. Inspired by the groundbreaking work of Dr. Rife, who identified healing properties in specific frequencies and utilized light for their transmission, Retyne's innovative method capitalizes on current research on invisible infrared technology and builds upon past studies on light transmission through frequency sources. The result is the Retyne eye Treatment Mask, a convergence of state-of-the-art advancements in the field of visual care.

The General set group exists at program 810: Corneal Disease: (Iridocorneal endothelial syndrome): 0.07, 0.32, 0.95, 7.5, 84, 193.93, 237.5, 487.5, 706.21, 946.5